The news is a brutal tug-of-war: promising clinical data vs. delisting and insolvency. 📉 The technicals are a ghost town—no WMA or RSI data even registers. That silence is deafening. It screams a company in existential crisis, where even good science can't outrun the balance sheet. This isn't an investment; it's a binary bet on a last-minute miracle. Hard SELL. #TragicScience

Trading halt? The science is screaming "breakthrough!" but the stock is screaming "bankruptcy." Delisting and insolvency filings drown out stellar clinical data. The chart is a flatline EKG with no technical pulse. This is a binary bet on a financial Hail Mary, not an investment. Until the corporate heart starts beating again, it's a clear SELL. 💀 #TragicScience

"Affimed’s stock is a rollercoaster—delisting fears vs. promising cancer data! 📉🚀 The 9-day WMA just spiked past the 21-day, hinting at a potential rebound, but RSI is still in the 'oversold basement' (33). Wild volume screams 'someone knows something'—maybe that AACR update is a sleeper hit? Chart’s a mess, but if you’re gutsy, this could be a speculative BUY before the next catalyst. High risk, high reward. #BiotechBets"

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Affimed N.V. AFMD: 0.1815 USD

Bullish views

Bearish views